PARP1 and pancreatic neoplasm: Olaparib is an FDA-approved PARP inhibitor that is widely used in ovarian cancer (Dizon, 2017), prostate cancer (Rebello et al., 2021), and pancreatic cancer (Park et al., 2021) treatment.